PT2073842E - Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos - Google Patents

Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos Download PDF

Info

Publication number
PT2073842E
PT2073842E PT78180908T PT07818090T PT2073842E PT 2073842 E PT2073842 E PT 2073842E PT 78180908 T PT78180908 T PT 78180908T PT 07818090 T PT07818090 T PT 07818090T PT 2073842 E PT2073842 E PT 2073842E
Authority
PT
Portugal
Prior art keywords
antibodies
expression
human cells
myeloid leukaemia
leukaemia origin
Prior art date
Application number
PT78180908T
Other languages
English (en)
Inventor
Steffen Goletz
Renate Stahn
Antje Danielczyk
Hans Baumeister
Anja LÖFFLER
Lars Stöckl
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39157600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2073842(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06090171A external-priority patent/EP1900750A1/en
Priority claimed from EP06090190A external-priority patent/EP1911766A1/en
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of PT2073842E publication Critical patent/PT2073842E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT78180908T 2006-09-10 2007-09-10 Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos PT2073842E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06090162 2006-09-10
EP06090171A EP1900750A1 (en) 2006-09-18 2006-09-18 Fully human high yield production system for improved antibodies
EP06090190A EP1911766A1 (en) 2006-10-13 2006-10-13 Use of human cells of myeloid leukaemia origin for expression of antibodies
EP07090094 2007-05-04

Publications (1)

Publication Number Publication Date
PT2073842E true PT2073842E (pt) 2015-04-07

Family

ID=39157600

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78180908T PT2073842E (pt) 2006-09-10 2007-09-10 Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos

Country Status (25)

Country Link
US (3) US9051356B2 (pt)
EP (5) EP3539981A1 (pt)
JP (3) JP5767779B2 (pt)
KR (3) KR101603632B1 (pt)
CN (1) CN103436574B (pt)
AU (1) AU2007294122B2 (pt)
BR (1) BRPI0716997B8 (pt)
CA (1) CA2662226C (pt)
CU (1) CU23791A3 (pt)
CY (1) CY1116279T1 (pt)
DK (2) DK2073842T4 (pt)
EA (1) EA017622B1 (pt)
ES (2) ES2533964T5 (pt)
FI (1) FI2073842T4 (pt)
HR (1) HRP20150307T1 (pt)
IL (1) IL197459A (pt)
MX (1) MX2009002388A (pt)
NZ (1) NZ575974A (pt)
PL (1) PL2073842T3 (pt)
PT (1) PT2073842E (pt)
RS (1) RS53861B1 (pt)
SG (1) SG174792A1 (pt)
SI (1) SI2073842T1 (pt)
WO (1) WO2008028686A2 (pt)
ZA (1) ZA201001903B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528611B2 (ja) * 1998-07-16 2004-05-17 Ｊｆｅスチール株式会社 結束材の切断方法及びその装置
KR101603632B1 (ko) 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008135259A2 (en) * 2007-05-04 2008-11-13 Glycotope Gmbh Antibody molecule composition
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
CN102292640B (zh) 2009-01-22 2014-07-02 动量制药公司 在来源于CHO细胞的糖蛋白产物中的含有半乳糖-α-1,3-半乳糖的N-聚糖
WO2011003615A2 (en) 2009-07-08 2011-01-13 Glycotope Gmbh Perfusion bioreactor
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
PT2603528T (pt) * 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
WO2012085162A1 (en) 2010-12-21 2012-06-28 Glycotope Gmbh Methods for culturing human myeloid leukaemia cells and cells derived therefrom
WO2012143499A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2741769B1 (en) * 2011-08-10 2019-01-02 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated antibodies
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2874658A1 (en) * 2012-07-18 2015-05-27 Glycotope GmbH Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JP2016504047A (ja) 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
BR112015019339A2 (pt) * 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
CA2900912A1 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
MX2015012825A (es) 2013-03-14 2016-06-10 Abbott Lab Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
EP3754012A1 (en) * 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
KR20150144804A (ko) 2013-04-22 2015-12-28 글리코토페 게엠베하 낮은 푸코실화를 갖는 항­ｅｇｆｒ 항체를 이용한 항암 치료
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015096982A1 (de) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
WO2015134696A1 (en) * 2014-03-05 2015-09-11 Ultragenyx Pharmaceutical Inc. Sialylated glycoprotein compositions and uses thereof
US20150307546A1 (en) * 2014-04-29 2015-10-29 Georgia Tech Research Corporation Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
CN108012545B (zh) 2015-03-31 2022-08-30 葛莱高托普有限公司 包含珠蛋白基因簇的调控元件的真核表达载体
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
CN108025084B (zh) 2015-06-22 2024-08-09 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
WO2016207328A1 (en) 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017070460A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
EP3472338B1 (en) 2016-06-20 2024-05-22 Octapharma AG Means and methods for modifying multiple alleles
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
WO2018114798A1 (de) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
WO2018138113A1 (en) 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP6829357B2 (ja) * 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
JP2020511959A (ja) 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー ヒト化抗ｃｄ４０抗体
JP2020512382A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
US20200131275A1 (en) 2017-03-29 2020-04-30 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
CA3074288A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC Methods, compositions and cells for preparing surfactant protein d (sp-d)
KR20200044955A (ko) * 2017-09-06 2020-04-29 에어웨이 테라퓨틱스, 아이엔씨. 계면활성제 단백질 d (sp-d)를 제조하는 방법 및 조성물
EP3759144A1 (en) 2018-03-01 2021-01-06 Glycotope GmbH Fusion protein constructs comprising an anti-muc1 antibody and il-15
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體
IL302538A (en) 2019-12-06 2023-07-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
US20230235076A1 (en) 2020-06-30 2023-07-27 Glycotope Gmbh Humanized antibodies against lewis y
AU2023234686A1 (en) 2022-03-16 2024-08-29 Pentixapharm Ag Antibodies against lypd3

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
EP0573551B1 (en) 1991-02-27 2003-05-21 Micromet AG Serine-rich peptide linkers
AU683413B2 (en) 1992-04-13 1997-11-13 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
WO1995010538A1 (en) * 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
AU3508300A (en) 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
AU754808B2 (en) * 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
JP2003510334A (ja) 1999-09-30 2003-03-18 コリクサ コーポレイション 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
FR2809312B1 (fr) 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
EP1333032A4 (en) * 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
ES2362413T3 (es) 2001-02-01 2011-07-05 Kabushiki Kaisha Yakult Honsha Procedimiento de evaluación del grado de acceso al intestino de bifidobacterium en alimento o bebida de leche fermentada.
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20050042714A1 (en) 2001-08-17 2005-02-24 Michael Pawlita Glycoconjugates of sialic acid derivates, methods for their production and use thereof
DK1438336T3 (da) * 2001-10-22 2006-10-02 Applied Research Systems Gonadotropiner til follikeldannelse
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
EP1451217A4 (en) 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
DE60334382D1 (de) 2002-08-16 2010-11-11 Glycotope Gmbh Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2425475T3 (es) 2003-08-18 2013-10-15 Glycotope Gmbh Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2005080585A1 (en) 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
US7374755B2 (en) 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
EP1987518A1 (en) * 2006-02-14 2008-11-05 Koninklijke Philips Electronics N.V. Bit detection for optical disc reading
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
KR101603632B1 (ko) 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
EP1911766A1 (en) 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1900750A1 (en) 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US8741365B2 (en) 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
JP2016504047A (ja) 2013-01-18 2016-02-12 グリコトープ ゲーエムベーハー タンパク質発現を向上させるための融合ペプチド
JP2015138634A (ja) 2014-01-22 2015-07-30 株式会社オートネットワーク技術研究所 端子金具付き電線及びその製造方法

Also Published As

Publication number Publication date
MX2009002388A (es) 2009-06-02
US20190359731A1 (en) 2019-11-28
KR20150126730A (ko) 2015-11-12
EP2073842A2 (en) 2009-07-01
ES2533964T5 (es) 2024-05-09
EP2428223A3 (en) 2012-05-16
EP2428224A2 (en) 2012-03-14
BRPI0716997B1 (pt) 2020-06-02
IL197459A (en) 2015-08-31
DK2428224T3 (en) 2017-03-27
HRP20150307T1 (hr) 2015-04-24
RS53861B1 (en) 2015-08-31
EP2428224B1 (en) 2016-12-21
CN103436574A (zh) 2013-12-11
US20150368363A1 (en) 2015-12-24
DK2073842T4 (da) 2024-01-15
JP6166303B2 (ja) 2017-07-19
EP2428224A3 (en) 2012-05-09
EA200970263A1 (ru) 2009-08-28
SI2073842T1 (sl) 2015-05-29
IL197459A0 (en) 2011-08-01
AU2007294122A1 (en) 2008-03-13
ES2620261T3 (es) 2017-06-28
CA2662226A1 (en) 2008-03-13
US9051356B2 (en) 2015-06-09
BRPI0716997A8 (pt) 2019-02-05
FI2073842T4 (fi) 2024-01-15
EP2428223A2 (en) 2012-03-14
CN103436574B (zh) 2016-08-10
KR20090077911A (ko) 2009-07-16
ES2533964T3 (es) 2015-04-16
WO2008028686A2 (en) 2008-03-13
JP5767779B2 (ja) 2015-08-19
CU23791A3 (es) 2012-03-15
EP2073842B2 (en) 2023-10-18
US10280230B2 (en) 2019-05-07
JP2010502204A (ja) 2010-01-28
BRPI0716997A2 (pt) 2013-10-15
EA017622B1 (ru) 2013-01-30
EP3539981A1 (en) 2019-09-18
KR20170021375A (ko) 2017-02-27
CA2662226C (en) 2020-08-04
BRPI0716997B8 (pt) 2021-05-25
PL2073842T3 (pl) 2015-06-30
JP2015146819A (ja) 2015-08-20
EP2073842B1 (en) 2014-12-31
DK2073842T3 (da) 2015-04-13
JP2017123879A (ja) 2017-07-20
KR101603632B1 (ko) 2016-03-16
NZ575974A (en) 2012-03-30
ZA201001903B (en) 2010-11-24
EP2428225A3 (en) 2012-05-09
US20100028947A1 (en) 2010-02-04
EP2428225A2 (en) 2012-03-14
SG174792A1 (en) 2011-10-28
CY1116279T1 (el) 2017-02-08
AU2007294122B2 (en) 2013-03-07
WO2008028686A3 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
PT2073842E (pt) Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
HK1223114A1 (zh) 抗因子 單克隆抗體及其使用方法
IL193604A0 (en) Methods of using antibodies against human il-22
EP2115664A4 (en) QUANTITATIVE ANALYSIS ON SKIN CHARACTERISTICS
HK1150839A1 (en) Compositions and methods of use for therapeutic antibodies
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
IL212856A0 (en) Human antibodies against human tissue factor
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
HK1108614A1 (en) Human body composition analyzer
IL212795A0 (en) Fully human antibodies against n-cadherin
HK1128237A1 (en) Further medical uses of antisecretory protein
ZA200901912B (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
EP2086592A4 (en) 2-LOW BASIC NITROIMIDAZOLES FOR NON-INVASIVE DETECTION OF TISSUE HYPOXIA
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
HU3350U (en) Device for covered introduction of scalpels
TWM300387U (en) Improved structure of cupulate holder